SHENZHEN, China, Aug. 27, 2025 /PRNewswire/ —

Key Highlights from the Financial Report:

• Revenue surged 404% year over year to RMB 517 million in the first half of 2025.
• Adjusted net profit reached RMB 141 million, marking the company’s first-ever half-year profitability.
• XtalPi was added to the MSCI China Small Cap Index, underscoring strong recognition of its investment value by the international capital markets.
• Significant breakthroughs and milestones were achieved across multiple business lines.

Drug Discovery Solutions: The Deep Integration of Advanced AI and Robotics Driving New Growth for Our Business

During the reporting period, revenue from our Drug Discovery Solutions business soared by 615.2% year-over-year, from RMB 60.85 million in H1 2024 to RMB 435.2 million. This growth was driven primarily by substantial upfront payments from major collaborations and multiple pipelines hitting key milestones.

1)   Landmark Collaboration with Professor Gregory Verdine

In late June, we signed a strategic collaboration with renowned biopharmaceutical scientist Professor Gregory Verdine. The agreement provides for an initial payment of US$51 million for the first phase, with an additional US$49 million in potential payments, and variable payments of up to US$ 5.89 billion subject to reaching regulatory and commercial milestones, along with potential royalties based on a single-digit percentage of the annual net sales of the products. This collaboration represents a key achievement in our global strategy and further validates the industry-leading capabilities of our AI+robotics drug discovery platform.

2)   Multiple Pipelines Achieve Breakthrough Milestones

• Chronic Disease Collaboration Ahead of Schedule: All three of our projects in collaboration with a leading biopharmaceutical company have successfully reached key milestones. Notably, a chronic disease program launched in 2024 achieved its PCC milestone a full quarter earlier than planned, highlighting the power of XtalPi’s fully integrated AI-computational-experimental platform in accelerating drug discovery.
• PRMT5 Inhibitor PE-0260 Advanced to IND: In close collaboration with PharmaEngine, we successfully developed the first-in-class PRMT5 inhibitor PE-0260. PharmaEngine has now completed IND application and initiated clinical trials.
• Prix Galien Award Nomination: The world’s first targeted therapy for diffuse gastric cancer, co-developed with incubated company Signet Therapeutics, was nominated for the prestigious Prix Galien Award for Best Biotechnology Product, often hailed as the “Nobel Prize of the pharmaceutical industry”. This was the only Asian pipeline nominated this year and only the fourth Chinese company to be nominated in the award’s 50+ year history.
• Antibody Business Growth: Thanks to high-quality deliveries of previously placed orders, in the first half of 2025, we recorded antibody business revenue nearly double that of full-year 2024. In this area, we now have partnerships ongoing with several globally renowned pharmaceutical companies, with our role evolving from a service provider to platform-based co-developer, significantly increasing customer lifetime value.
• Breakthroughs at XtalPi-incubated Leman Biotech: (1) Leman’s metabolically enhanced CD19 CAR-T therapy successfully treated multiple systemic lupus erythematosus (SLE) patients, while its solid tumor CAR-T program advanced rapidly toward investigator-initiated trial (IIT) readiness. (2) Leveraging AI-driven optimization and high-throughput experiments, we improved the binding affinity and immune activity of its core metabolic enhancers, enabling the project to advance into IIT preparation in the first half of 2025.

3)   Enhancing AI Capabilities to Create a Drug Discovery Superintelligence

• We have developed over 200 AI models spanning molecular generation, free energy perturbation (FEP), property prediction, and crystal structure prediction. In the first half of 2025, building on our earlier strategic partnership with Pfizer, we continued to iterate and optimize these models while deepening our collaboration to co-develop a next-generation, AI-driven molecular simulation platform. Additionally, we are actively expanding the platform’s capabilities across diverse applications, including small molecules, peptides, and antibodies, to comprehensively empower Pfizer’s drug discovery efforts.
• We launched a new Ultra mode for our AI antibody development platform XtalFold^®, improving antigen-antibody complex prediction accuracy by approximately 10 percentage points. In July, our self-developed AI antibody drug structure modeling platform XtalFold^® was honored one of the “Top 10 AI Innovations (Technologies/Products)” at the World Artificial Intelligence Conference (WAIC).
• We initiated the development of a Molecular Glue platform built around a Design — Make — Test — Analyze (DMTA) closed-loop framework in new drug development. Our core Molecular Glue team is now in place and has established initial collaboration with key opinion leaders from both industry and academia. Meanwhile, the team is conducting in-depth discussions with multiple pharmaceutical companies on specific targets and screening strategies. Initial feedback has been positive, and partnership intentions are steadily progressing.
• We launched PepiX™, a global-leading peptide and protein R&D platform that integrates generative AI molecular design, automated synthesis, trillion-scale peptide libraries, and high-throughput screening. Early results include:
  • In AI-driven cancer vaccine development, candidate molecules designed by the platform have demonstrated strong immunogenicity in preclinical animal models and are poised to enter clinical trials
  • Two independently developed oral peptide health products for blood sugar regulation and fat reduction have completed efficacy and toxicology evaluations and are now entering the regulatory approval process.
  • A successful first-in-class renal cancer target development project with National Cancer Centre Singapore (NCCS) is progressing to downstream efficacy validation.

We have also built a library of over 2,000 non-natural amino acid monomers, fully parameterized for computational modeling, enhancing molecular design and exploration.

• At the AAAI (Association for the Advancement of Artificial Intelligence) 2025, we presented our breakthrough research mRNA2vec, an AI-driven technology that optimizes mRNA sequence design, enhancing expression levels and stability while addressing the high costs and lengthy timelines of traditional screening methods, establishing a new paradigm for intelligent mRNA designs.

Intelligent Robotics Solutions: AI and Robotics Driving a Transformation in Chemistry

Revenue from our Intelligent Robotics Solutions business grew 95.9% year-over-year to RMB 81.9 million in the first half of 2025, fueled by the rapid growth from our automated chemical synthesis services and our XtalPi R&D solutions.

1)   AI + Robotics Reshape the R&D Paradigm, Building Vertical Artificial Superintelligence

We have built a unique flywheel system integrating high-throughput experiments, high-quality data, and advanced AI models. Our robotics lab operates 24/7, generating vast volumes of high-quality data to power vertical AI models. This paradigm is transforming traditional R&D approaches, accelerating breakthroughs in both drug and material development.

Our AI models and robotic laboratory have been widely applied across the field of chemistry, significantly expanding the accessible chemical space, overcoming critical bottlenecks in drug and new material molecule development, and effectively accelerating delivery timelines. During the reporting period, we also made significant progress in several key technologies:

• The Future of Chemistry: Innovation Breakthroughs Powered by Models and Data
  • In the chemical reaction stage, leveraging extensive experimental data from our robotics lab and knowledge graphs obtained via the LLM-powered literature search tool PatSight, we have successfully developed AI models for synthetic feasibility prediction and reaction condition recommendation covering common reaction types.
  • In practical applications, these models have boosted the success rate of predicting chemical reaction success rates to over 85%.
  • In the separation and purification phase, we developed reaction condition recommendation and yield prediction models tailored for condition screening, which have been successfully applied in multiple client projects. In two of these projects, yields exceeded 50%.
  • Additionally, we have completed the acquisition of Liverpool ChiroChem (LCC), a company with deep expertise in chiral chemistry, strengthening our capabilities in chemical space exploration. LCC boasts a world-leading library of chiral molecules and a high-quality database, offering significant advantages in molecular quality and diversity and providing strong data support for AI-driven exploration of the chiral chemical space.
• Breakthrough in Embodied Intelligence: “NeoDispenser” Solves Key Challenges in Robotic Laboratories

In the first half of 2025, we achieved significant breakthroughs in robotic laboratories, notably advancing embodied intelligence technology. We successfully developed a new generation of modular robotic systems that integrate advanced visual perception, AI, and robotic technologies to tackle some of the most challenging problems in chemical research.

For example, our next-generation modular robot features our patented “NeoDispenser,” a flexible gripper that successfully mimics human hand operations with exceptional dexterity, earning recognition from top global clients. This design addresses three major industry challenges: (1) precise handling of trace powders; (2) overcoming traditional solutions’ poor adaptability to different powders; (3) eliminating intermediate containers to reduce costly material waste.

• Multi-Agent Systems Driving a Revolution in Chemistry: From Massive Chemical Space Exploration to Fully Autonomous Decision-Making

In the first half of 2025, we successfully built a cost-effective, high-performance data platform capable of predicting synthetic feasibility across hundreds of billions of chemical compounds.

• LLM-powered drug R&D data extraction — PatSight Patent Mining Platform Accelerates Structure Analysis

Our PatSight patent mining platform, jointly developed and iterated with the IDEA Research Institute, has achieved breakthrough progress powered by LLMs and deep neural network technologies. The platform can efficiently extract core data from literature and patents, such as molecular structures, activities, pharmacological effects, and reactions, with an accuracy rate of up to 97%, significantly enhancing the efficiency of structure analysis and data acquisition. PatSight overcomes the inefficiencies of traditional manual processing, providing high-quality public big data support for AI4S models in specialized domains. In the first half of 2025, the platform secured multiple procurement and collaboration agreements with domestic and multinational pharmaceutical companies.

• By consistently upgrading the materials research platform and exploring applications across multiple material domains, we have continued to expand our technological applications across new chemical materials, including adhesives, coatings, electrolytes, catalysts, and advanced carbon materials. We have also secured orders from several leading companies in the materials sector, with overall project progress advancing smoothly.

2)   XtalPi R&D Solutions Achieve Global Commercial Breakthroughs

As our technological capabilities continue to grow, our XtalPi R&D solutions have gained strong customer recognition and are rapidly expanding into international markets. During the reporting period:

• We signed a multi-million US Dollar agreement with South Korea-based JW Pharmaceutical, one of Asia’s leading pharmaceutical companies. Under the deal, XtalPi will deliver a comprehensive solution that includes a high-throughput automated synthesis workstation, an AI-driven reaction condition optimization system, and an intelligent analysis platform. Featuring Bayesian optimization algorithms, digital experiment management, and advanced automated lab technologies, this integrated solution will significantly boost synthesis success rates and repeatability while shortening drug development cycles. The collaboration will provide JW with a robust technological foundation to accelerate breakthrough pipeline development in oncology, metabolic diseases, and other key areas, fast-tracking more globally competitive drug candidates into clinical trials.
• We signed a multi-million US Dollar cooperation agreement with Liangzhu Laboratory. Under this partnership, XtalPi and Liangzhu will collaborate on setting up a robotics-powered biomaterials laboratory, with XtalPi providing a smart robotics platform spanning their entire workflow from synthesis to testing.
• We entered into a key partnership with Roche, under which XtalPi will integrate robotics, transport and barcode scanning modules, stacker cranes, and automated pallet and tube handling systems to enable automated sorting, high-throughput storage, and precise retrieval of molecular building blocks.

PROSPECTS AND OUTLOOK

We believe the future of scientific discovery lies in the seamless fusion of artificial intelligence, embodied intelligence, and human insight. We are boldly tackling challenges to unlock new frontiers, transforming technological barriers into breakthroughs and visionary ideas into impactful solutions. By building superintelligent systems for life and materials sciences, we seek to reshape the future of human civilization through a pioneering new research paradigm.

About XtalPi

XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.

Investor Relations Contact:

In China:

XtalPi Holdings Limited
Investor Relations
Email: ir@xtalpi.com

Piacente Financial Communications
Tel: +86-10-6508-0677
Email: XtalPi@thepiacentegroup.com

In the United States:

Piacente Financial Communications
Brandi Piacente
Tel: +1-212-481-2050
Email: XtalPi@thepiacentegroup.com

Start Your Journey to Access Vast Chemical Space

CHENGDU, China, Aug. 27, 2025 /PRNewswire/ — Developing new medicines demands smart technology and powerful tools. DNA-encoded library (DEL) technology, with its unique ability to rapidly screen billions of compounds to identify small molecule hits, has transformed drug discovery. HitGen Inc. is raising the bar with the introduction of OpenDEL™ 5.0 – featuring a total of 4 billion diverse compounds designed to tackle challenging biological targets. OpenDEL™ 5.0 comes in a convenient kit format that is accessible to scientists in industry and academia alike.

Key Improvements:

Expanded Chemical Diversity: 4 billion Compounds

• Increased Library Size: Now with 25% more compounds, OpenDEL™ 5.0 offers 3.8 billion small molecules compounds and 200 million peptide compounds to further expand chemical space for targeting protein-protein-interactions (PPI).
• Encompassing Library Design: 59 distinct libraries provide a broad range of chemistries to address different types of targets and discovery challenges. 

Optional Macrocycle Library: Unlocking Challenging Targets

• A dedicated macrocycle library: Available as an add-on, featuring 4-10 amino acids in the ring. Comes with a linear peptide control library.
• Dual-Kit Flexibility: Choose between OpenDEL™-Small Molecules or OpenDEL™-Macrocycle – or combine both for maximum coverage.

Streamlined Workflow & Faster Access

• Redesigned protocols: Intuitive visual guides simplify key steps, reducing onboarding time.
• Expedited delivery: Next-day shipping available to minimize wait time

Begin Your Exploration Today

OpenDEL™ 5.0 is now available worldwide. Let HitGen help you with your next drug discovery breakthrough.

Visit www.hitgen.com or contact our team to learn more.

SHENYANG, China, Aug. 27, 2025 /PRNewswire/ — Neusoft Medical Systems today announced that its NeuViz P10 photon-counting CT has received market approval from China’s National Medical Products Administration (NMPA). This marks the first photon‑counting CT approved in China, and the world’s first wide‑body system equipped with an 8‑cm detector.

Photon-counting CT (PCCT)  is considered a breakthrough in next‑generation imaging. Unlike conventional CT scanners, which first convert X‑rays into light before generating digital images, the NeuViz P10 uses a cadmium zinc telluride (CZT) detector to capture and convert each X‑ray photon directly into a digital signal. This direct approach delivers images with far greater clarity, reduces radiation exposure for patients, and improves the ability to distinguish between different types of tissue.

For patients, these advances mean clearer visualization of tiny blood vessels in the heart, earlier detection of small tumors, more accurate identification of neurological conditions, and safer lung examinations with reduced exposure to radiation. The system’s ultra-high resolution also helps doctors detect diseases at earlier stages, when treatment can be more effective and outcomes significantly improved.

To maximize clinical and research value, the NeuViz P10 integrates four innovation platforms: NeuPhoton Counting, Photon Supersonic, Photon Intelligence, and Photon Research. Together, these platforms deliver faster scans, safer imaging, intelligent workflow support, and expanded opportunities for clinical research.

“The approval of NeuViz P10 is a milestone for China’s medical imaging industry and for global CT innovation,” said Patrick Wu, CEO of Neusoft Medical Systems. “This technology empowers radiologists with clearer images at lower doses, giving patients earlier and more accurate answers while delivering maximum clinical value for public health.”

About Neusoft Medical Systems

Neusoft Medical Systems is a global leader in medical imaging solutions and services. The company is dedicated to integrating AI technologies with medical imaging to deliver intelligent, efficient, precise, and reliable products and services. By building a comprehensive healthcare ecosystem, Neusoft Medical Systems enhances the accessibility and equity of global healthcare.

By the end of 2024, Neusoft Medical Systems had a presence in over 120 countries and regions, serving more than 14,000 customers, with a historical installed base exceeding 50,000 units.

Learn more about us: www.neusoftmedical.com/en

Lineup at ShowStoppers and IFA showcases charging, protection, and productivity, redefining Tech Made Easier

WILMINGTON, Del., Aug. 27, 2025 /PRNewswire/ — ESR, a global tech brand trusted by over 123 million users, will present its newest innovations at IFA 2025 from September 5–9 at Messe Berlin. Guided by its mission “Tech Made Easier,” ESR is set to unveil industry-first accessories that deliver wired-speed magnetic charging, stronger device protection, and more flexible productivity.

Among the highlights are upgraded CryoBoost®–enabled chargers with Qi2.2 25W wireless charging optimized for the latest iPhones, all-new cases and screen protectors engineered for Apple’s redesigned camera layout, and next-generation detachable iPad keyboards designed for flexible productivity on the go. ESR will also spotlight its growing range of smart accessories, including the snap-to-carry MagMouse and Find My–integrated wallets, underscoring the brand’s expansion into a full ecosystem that powers, protects, and simplifies tech across devices.

“At ESR, we believe technology should simplify life,” said Tim Wu, CEO of ESR. “Each product in our 2025 IFA lineup is built to enhance the way people interact with their devices—more intuitively, more efficiently, and with greater ease. We look forward to sharing these innovations with the world at IFA.”

Wired-Speed in a Snap: Speed Meets Convenience

At IFA 2025, ESR is unveiling its most advanced wireless charging ecosystem yet, built around Qi2.2 25W speed and its exclusive CryoBoost® phone cooling tech—a patented system that tackles wireless charging’s biggest limitation: heat.

First introduced in 2022, CryoBoost® redefined MagSafe charging with active phone cooling. The new CryoBoost® takes it further with an open duct design and a slimmer 4 mm fan that keeps operation 6.5°F cooler than other brands, whisper-quiet at 25 dB, and is seamlessly integrated into the charger’s compact form.

Paired with Qi2.2, ESR’s lineup delivers wired-level speed with magnetic convenience and efficiency, optimized for all compatible iPhones and beyond. With options ranging from home stations to car to travel-ready chargers, all capable of powering multiple devices at once, ESR sets a new standard for cool, clutter-free, and reliable magnetic charging anywhere.

Ultimate Protection All-Around: Strength with Versatility

With Apple’s latest iPhone introducing a redesigned, more prominent camera module, ESR is raising the bar on protection. Its latest cases are engineered for comprehensive impact defense, combining dual-layer camera shields, reinforced Air Guard corners, and a built-in Camera Control cover to safeguard delicate lenses from everyday drops, scratches, and scuffs.

Merging protection with usability, each case features ESR’s patented Stash Stand—a seamlessly integrated kickstand that supports both portrait and landscape viewing while still allowing full use of MagSafe. Whether for Zoom calls, video streaming, or hands-free reading, it offers reliable functionality without added bulk.

Completing the ecosystem is the new UltraFit Armorite® Pro Screen Protector, built with Corning™ Glass for superior scratch resistance and absorbing 10× more impact than generic protectors. Optimized to match the anti-reflective finish of the latest iPhone’s display, it minimizes glare while preserving color accuracy and touch sensitivity. With the included UltraFit Tray, users get a quick, bubble-free installation—no learning curve required.

Detachable iPad Keyboard Cases: Flexibility for Every User

As iPads continue to blur the line between tablet and laptop, ESR’s new Shift and Flex detachable keyboard cases deliver the best of both worlds—mobility and productivity without compromise. With a magnetic, detachable design connected via Bluetooth and multi-angle support, they adapt seamlessly for typing, sketching, viewing, or reading in any setting.

Built for professionals, students, and creators, both models feature full-size keys and edge-to-edge trackpads for laptop-level control, yet remain lightweight and compact, preserving the iPad’s intuitive, touch-first experience. It’s a true fusion of tablet freedom and laptop power—wherever it’s needed.

Smart Accessories: Innovation in Every Detail

The Magnetic Wallet Stand with Find My integration gives users peace of mind by combining everyday carry with seamless tracking, ensuring essentials are always safe and close at hand. The snap-to-carry MagMouse, backed by a successful crowdfunding campaign and honored with a Future Innovation Award, attaches magnetically to laptops for effortless portability, turning mobile work into a smoother, more convenient experience.

Together, these products highlight ESR’s expansion into a broader ecosystem—solutions that power, protect, and simplify how people live and work, all while staying true to the brand’s mission of “Tech Made Easier.”

Visit ESR at IFA 2025:

• ShowStoppers Media Event: Sept 4, 6:00 p.m.–9:00 p.m. CET
• IFA Booth: Sept 5–9, Messe Berlin (Booth H3.2-114)

Discover more about ESR’s latest innovations at Amazon or ESR’s official site. To arrange IFA meet-ups, request review samples,or media inquiries, reach out to media@esrtech.com. 

About ESR: Trusted for 16 Years

Founded in 2009, ESR is a global tech brand trusted by over 123 million customers worldwide. We design tech accessories for smart devices to enhance everyday tech experiences. We’re on a mission to make tech easier to use—developing products that seamlessly integrate into daily life, helping people live with greater ease and efficiency. To stay updated on the latest news and product launches from ESR, please visit www.esrtech.com or follow ESR’s social media on X, Instagram, and Facebook.

The playful collaborations reimagine two iconic worlds for all ages—just in time for fall.

LOS ANGELES, Aug. 27, 2025 /PRNewswire/ — SHEIN, the global online fashion and lifestyle retailer, today unveiled two exclusive collections rooted in play: MY LITTLE PONY and TRANSFORMERS. Designed to celebrate the joy and adventure of these childhood favorites, the collections are a must for fans of all ages gearing up for the back-to-school season.

From the original pony Starshine and the fan-favorite Twilight Sparkle to Autobots Bumblebee and Optimus Prime, each collection brings beloved characters to life with bold hoodies, graphic tees, and playful, affordable apparel for kids, women, and men. Whether you’re twinning with your little one or adding nostalgia and fun to your look, these styles deliver classic charm with a modern twist.

Together, the drops include 91 pieces across kids’ and adults’ sizes—including curve and menswear—making it easy for the whole family to channel magical adventures filled with sparkles and friendship for everypony, or activate your alt mode with fashion that’s …MORE THAN MEETS THE EYE.

To shop and explore the full collections, visit SHEIN.com.

About SHEIN

SHEIN is a global online fashion and lifestyle retailer offering SHEIN-branded apparel and products from a global network of vendors, all at affordable prices. Headquartered in Singapore, SHEIN is committed to making the beauty of fashion accessible to all, promoting its industry-leading, on-demand production methodology for a smarter, future-ready industry. To learn more about SHEIN, visit www.sheingroup.com.

NEW YORK, Aug. 27, 2025 /PRNewswire/ — Rokid, a pioneer in human-computer interaction and augmented reality, today officially unveiled the Rokid Glasses in New York City, the world’s lightest full-function AI & AR smart glasses, marking a milestone in the evolution of wearable AI computing.

Rokid Glasses are lightweight (49g) AI-powered AR smart glasses with a built-in 12MP first-person camera, Micro LED waveguide displays, and integrated audio. Designed for both consumer and professional use, they offer real-time translation, object recognition, navigation, transcription, notifications, and other AI-driven functions in a discreet, all-day wearable.

The Rokid Glasses are the world’s lightest camera-equipped smart glasses that combine augmented reality visuals, audio, and AI-powered features in a single device. Built on the Qualcomm AR1 platform, they strike a balance of style, performance, and industrial-grade reliability, making them ideal for everyday life.

Built on Developer Power

Behind Rokid Glasses is the largest XR developer community in China, comprising over 15,000 developers and 5,000 corporate developers who have already leveraged Rokid’s open SDK and platform resources. This year, Rokid is taking this ecosystem to the global stage, aiming to bring over 1,000 overseas developers into its network. This expansion will include localized apps, use cases, and services for users worldwide.

Rokid has also partnered with over 50 universities worldwide, engaging more than 5,000 students and faculty through hackathons, certification programs, and training initiatives. To date, more than 200 academic and industry projects have been developed using Rokid’s SDK and cloud platform, supported by active developer groups and forums. This vibrant network ensures that Rokid Glasses is backed by a global platform that will drive next-generation Human-Computer Interactions.

Specialist Insights: Panel on AI Glasses

The launch featured the thought-leadership panel “From Mobile to Wearable: The Rise of AI Glasses”, where experts explored the shift from smartphones to wearable AI devices and the broader implications for communication, industry, and accessibility.

The panel featured Andrea Smith, technology journalist with CNN Underscored and former ABC News correspondent; Dr. Vasant Dhar, Professor at NYU Stern School of Business and the Center for Data Science and founder of SCT Capital Management; Dr. Orson Xu, Assistant Professor at Columbia University specializing in human-computer interaction and AI for health; and Dr. Shawn Shen, founder of Memories AI and former research scientist at Meta.

Topics ranged from the adoption curve of AI glasses to their impact on human-computer interaction, healthcare applications, privacy, trust, and the future role of wearable AI in society.

Podcast: AI Glasses For Social Good

As part of the launch, Rokid introduced a special podcast session titled “AI Glasses For Social Good.” This discussion featured Liang Guan, Head of Global Partnership Development at Rokid, in conversation with two executive speakers from CaringKind, New York City’s leading expert on Alzheimer’s and dementia caregiving.

CaringKind brings over 40 years of experience in supporting families and individuals affected by dementia, providing training, resources, and advocacy. Together, Rokid and CaringKind explored how AI-powered glasses can enhance accessibility, caregiving, and memory support, giving valuable applications for communities facing cognitive decline and related challenges.

Storytellers Kick Off Rokid World Tour

The launch also marked the beginning of Rokid’s “Dream Journey” World Tour, a global initiative designed to showcase how AI glasses integrate into real-life scenarios while fostering collaboration with creators worldwide.

The inaugural storytellers, Jesse Torres, Max Manausa, Jocelyn Chiu, and Liee Ying, will embark on dream itineraries funded by Rokid. From a skateboarder chasing foreign streets, to a tech analyst testing how wearables fit into fast-paced travel schedules, to a couple capturing the joy of their honeymoon, each will share their personal journeys through the lens of Rokid Glasses. Together, these stories will build a broader narrative that highlights the real-world impact of AI-powered wearables, moving beyond technical demonstrations to meaningful, human-centered experiences.

Kickstarter Momentum

Following the unveiling, Rokid Glasses reached 400,000 USD in just 8 hours on Kickstarter, demonstrating strong global demand for intelligent, lightweight wearable computing.

“Today’s launch is not the end of a journey – it is the beginning of a new chapter,” said Zoro Shao, Global General Manager of Rokid. “With Rokid Glasses, we are not only shaping the future of AR, but also creating a future where technology removes barriers and empowers everyone.”

Rokid Glasses is now available for early supporters on Kickstarter, offering backers the chance to be the first to experience the future of AI-powered wearable computing.

About Rokid

Rokid is a product-oriented platform company with a focus on human-computer interaction for over ten years. As a pioneer in augmented reality, Rokid develops both hardware and software for AR headsets and their surrounding ecosystem, with a mission to ensure that the magic of AI and AR leaves no one behind. With the largest XR developer community in China, its products are consistently regarded among the best wearable devices in the country. It has won the Las Vegas CES Innovation Award for three consecutive years and the German IF Design Award five times.